Identification and evaluation of a novel glucokinase allosteric activator in target cells and animal model of type 2 diabetes

被引：0
|
作者：
Nagata, Y
Sasaki, K
Hosaka, H
Ooyama, S
Kadotani, A
Goto, H
Futamura, M
Nishimura, T
Iino, T
Bamba, M
Watanabe, H
Suzuki, J
Li, ZH
Moller, DE
Zhang, BB
Eiki, JI
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A139 / A139
页数：1
相关论文
共 50 条
  • [41] Dedifferentiated beta cells may cause Type 2 diabetes and represent a novel therapeutic target
    不详
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (06) : 591 - 591
  • [42] Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
    Chow, Elaine
    Wang, Ke
    Lim, Cadmon K. P.
    Tsoi, Sandra T. F.
    Fan, Baoqi
    Poon, Emily
    Luk, Andrea O. Y.
    Ma, Ronald C. W.
    Ferrannini, Ele
    Mari, Andrea
    Chen, Li
    Chan, Juliana C. N.
    DIABETES, 2023, 72 (02) : 299 - 308
  • [43] Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
    Wilding, J. P. H.
    Leonsson-Zachrisson, M.
    Wessman, C.
    Johnsson, E.
    DIABETES OBESITY & METABOLISM, 2013, 15 (08): : 750 - 759
  • [44] TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes
    Egan, Aoife
    Vella, Adrian
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (09) : 741 - 747
  • [45] Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs
    Eiki, Jun-ichi
    Nagata, Yasufumi
    Futamura, Mayumi
    Sasaki-Yamamoto, Kaori
    Iino, Tomoharu
    Nishimura, Teruyuki
    Chiba, Masato
    Ohyama, Sumika
    Yoshida-Yoshimioto, Riki
    Fujii, Kenji
    Hosaka, Hideka
    Goto-Shimazaki, Hiroko
    Kadotani, Akito
    Ohe, Tomoyuki
    Lin, Songnian
    Langdon, Ronald B.
    Berger, Joel P.
    MOLECULAR PHARMACOLOGY, 2011, 80 (06) : 1156 - 1165
  • [46] Novel hormone potential new target in Type 2 diabetes
    Patel, Jitesh
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (04) : 321 - 321
  • [47] Pyruvate Carboxylase, a Novel Therapeutic Target for Type 2 Diabetes
    Kumashiro, Naoki
    Beddow, Sara A.
    Fat, Ioana
    Majumdar, Sachin K.
    Guebre-Egziabher, Fitsum
    Christianson, Jennifer L.
    Manchem, Prasad
    Monia, Brett P.
    Bhanot, Sanjay
    Shulman, Gerald I.
    Samuel, Varman T.
    DIABETES, 2011, 60 : A460 - A460
  • [48] TTP399, a Liver Selective Glucokinase Activator, Increases Efficacy of Currently Marketed Therapies for Type 2 Diabetes
    Valcarce, Carmen
    Fong, Tung M.
    DIABETES, 2015, 64 : A330 - A330
  • [49] Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus
    Georgy, Angela
    Zhai, Suoping
    Liang, Zhenming
    Boldrin, Mark
    Zhi, Jianguo
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (06): : 675 - 682
  • [50] Impairment of glucokinase translocation in cultured hepatocytes from OLETF and GK bats, animal models of type 2 diabetes
    Toyoda, Y
    Ito, Y
    Tanigawa, K
    Miwa, I
    ARCHIVES OF HISTOLOGY AND CYTOLOGY, 2000, 63 (03) : 243 - 248
12345